Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss
about
Promoting myelin repair and return of function in multiple sclerosisA herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunityStem cell therapy for central nerve system injuries: glial cells hold the keyRole of cytokine signaling during nervous system developmentFrom fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases.Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve.The pathogenesis of murine coronavirus infection of the central nervous system.Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice.Leukemia inhibitor factor promotes functional recovery and oligodendrocyte survival in rat models of focal ischemia.Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism.EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE)Targeting oligodendrocyte protection and remyelination in multiple sclerosis.Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation.Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis miceCellular approaches for stimulating CNS remyelination.Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS.miR-17-92 facilitates neuronal differentiation of transplanted neural stem/precursor cells under neuroinflammatory conditions.Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination.Leukemia inhibitory factor regulates the timing of oligodendrocyte development and myelination in the postnatal optic nerve.Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis.LIF in the regulation of T-cell fate and as a potential therapeutic.Roles of NG2 glial cells in diseases of the central nervous system.Achieving CNS axon regeneration by manipulating convergent neuro-immune signaling.Oligodendroglia and neurotrophic factors in neurodegeneration.Neurotrophic factors and their effects in the treatment of multiple sclerosis.Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor.CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis.Neuroinflammation facilitates LIF entry into brain: role of TNFiPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution.Candidate molecular pathways of white matter vulnerability in the brain of normal aging rhesus monkeys.
P2860
Q26862803-3A566824-F35E-4C15-A93F-F5F9EF3542CFQ27319470-13420D18-7D40-4554-B6D3-BE83ABC4DB9CQ28394140-D9771FAD-B5F1-4A3B-978B-B6DDD84960B5Q30450870-732B2EA7-6A46-4045-8F7C-73E1E45C551BQ31155244-75A3D903-DE7A-415F-8810-90E6C4119DE9Q33692583-E66AF840-934A-49DA-B6C4-43ABF22F7E3DQ33779927-B18AE8D6-85A7-4048-9EF8-807CAA73CCA3Q33911059-46DC9B9D-DB41-4755-AE09-90687805F11CQ34308344-67013CBF-10DB-4BC7-A653-B1019DC77226Q34450780-E1AC727E-6E97-43FC-8C56-1DBF2B8F05A2Q34580168-BC6140FA-95EC-4E88-8BA2-FA5F08BE4A3FQ34782075-B3848F51-4399-4558-89A4-C01A65A04376Q35140044-6A7FFDD2-D6A7-4738-9DC1-D1808B020D53Q35722755-FEA09D7B-FCD2-44CA-A903-757D73664411Q36260857-63D17DB2-D126-46D9-B965-A71D51AE24BAQ36956709-1E49D82C-43F6-4F8B-A451-51A17A2CD6B6Q37012791-7C21C1C0-6B51-41EF-929F-21BCB33430A0Q37212103-1C5A92DF-2D89-4D89-A2C2-12DD4E8CF4B1Q37352392-2326DDC3-418C-4479-A82F-0999D1FF9CDCQ37434691-71C89D33-A792-41D4-B3AA-BE9327F270A2Q37484945-6498D375-E289-450B-8F60-B28E659B2D30Q37849132-C61E29EA-58B3-45D8-B6C7-71B338F2EA83Q37959796-27BA81A9-E5BF-46C6-AFCD-950777A9A11BQ38010639-883C0AF0-7238-46C0-810E-D64E37481927Q38096248-AA5261EC-DF72-42EA-914B-733B47DCCE1AQ38388778-54F08609-FB80-4222-8ACB-A33A740B6677Q39047793-18B622C9-935C-44AB-9AE4-578AEAF966BDQ40295296-BEA32C35-F075-4EFA-941E-4DB56E880680Q42550809-64912A12-88EB-4586-938F-D9DC02C52B57Q45824204-347C93C0-8E49-4EF7-AACB-138DEB582F07Q54218847-CC336FAE-8B6C-4A97-A210-C7A6E744EE47Q54917621-E723042E-35FB-4C98-A926-CA09E95FE19D
P2860
Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss
description
article
@en
im Mai 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2006
@uk
name
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@en
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@nl
type
label
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@en
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@nl
prefLabel
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@en
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@nl
P50
P356
P1433
P1476
Endogenous leukemia inhibitory ...... ation and oligodendrocyte loss
@en
P2093
Mark P Marriott
Tania Cipriani
P304
P356
10.1002/GLIA.20321
P577
2006-05-01T00:00:00Z